Connect with us

Science

The U.S. Is Funding Fewer Grants in Every Area of Science and Medicine

Published

on

The U.S. Is Funding Fewer Grants in Every Area of Science and Medicine

Advertisement

National Institutes of Health competitive grant funding

Advertisement

In the past decade, the National Institutes of Health awarded top scientists $9 billion in competitive grants each year, to find cures for diseases and improve public health.

This year, something unusual happened…

This year, something unusual happened…

Advertisement

Starting in January, the Trump administration stalled that funding. By summer, funding lagged by over $2 billion, or 41 percent below average.

Advertisement

But in a surprising turn, the N.I.H. began to spend at a breakneck pace and narrow this gap.

Advertisement

There was a catch, however: That money went to fewer grants.

Which means less research was funded in areas such as aging, diabetes, strokes, cancer and mental health.

Advertisement

Which means less research was funded in areas such as aging, diabetes, strokes, cancer and mental health.

Advertisement

Includes new grants and competitive grant renewals. In 2025 dollars.

To spend its budget, the N.I.H. made an unusual number of large lump-sum payments for many years of research, instead of its usual policy of paying for research one year at a time.

As a result of this quiet policy shift, the average payment for competitive grants swelled from $472,000 in the first half of the fiscal year to over $830,000 in the last two months.

Advertisement

While this might sound like a boon for researchers, it’s actually a fundamental shift in how grants are funded — one that means more competition for funding, and less money and less time to do the research.

Advertisement
Advertisement

In the past, the N.I.H. typically awarded grants in five annual installments.

Advertisement

Researchers could request two more years to spend this money, at no cost.

Advertisement

Under the new system, the N.I.H. pays up front for four years of work.

Advertisement

And researchers can get one more year to spend this money.

Advertisement

Which means that they get less money on average, and less time to spend it.

And because these fully funded grants commit all of their money up front, it means the agency’s annual budget is divided into fewer projects, instead of being spread among a larger number of scientific bets.

Advertisement

The new policy directive came from the White House’s Office of Management and Budget, which in the summer instructed the N.I.H. to spend half of its remaining funds to fully fund research grants. In the past, the agency would do so only in special circumstances.

The White House has said this would “increase N.I.H. budget flexibility” by not encumbering its annual budget with payments to previously approved projects. It has said it plans to continue this policy in 2026, while proposing to shrink the agency’s budget by $18 billion, or nearly 40 percent. (The Senate and House rejected the White House’s proposed budget cuts, but have not yet agreed on the agency’s budget.)

Advertisement

“My sense of it was that the administration wanted to clear the decks,” said Sarah Kobrin, a branch chief at the N.I.H.’s National Cancer Institute, who said she was sharing her views, not those of the institute.

The new policy is being carried out as the Trump administration has tightened its hold over federal science funding. Earlier this year, it delayed reviewing grants in order to vet research by political appointees, culled projects that mentioned D.E.I. and fired thousands of employees or pressured them to retire early. (The N.I.H. lost nearly 3,000 employees this year, or about 14 percent of its work force, based on a New York Times review of the agency’s shutdown contingency plans.)

“They brought everything to a stop,” Dr. Kobrin said.

Advertisement

Nonetheless, the N.I.H. managed to spend most of its budget by the end of the fiscal year. “My colleagues did an outstanding job to work their butts off to approve things,” said Theresa Kim, a program officer at N.I.H.’s National Institute on Aging.

Something similar happened at the National Science Foundation, which is the second-largest federal funder of research at U.S. universities, after the N.I.H.

Advertisement

The N.S.F. started the year with funding delays caused by the Trump administration, and it lost about a third of its employees in layoffs or forced retirements. The agency ended the year awarding 25 percent fewer new grants.

Advertisement

New grants awarded by the National Science Foundation, 2015–25

Facing a proposed $5 billion cut to its $9 billion budget, the N.S.F. fully paid off many of the grants that were on its books, a strategy that employees called “paying down the mortgage.” It also paid for nearly all new awards upfront (though, unlike at the N.I.H., not necessarily for less time and money).

To draw these conclusions, The Times used public data to analyze nearly every competitive grant — over 300,000 in all — that the N.I.H. and the N.S.F. awarded since 2015, and interviewed many employees at these agencies.

Advertisement

Here’s what we found:

1. Fewer grants in every area of science and medicine

Advertisement

Together, the N.I.H. and the N.S.F. had a nearly $60 billion annual budget for funding future breakthroughs in science and medicine, about a quarter of which is typically spent on new grants or competitive renewals.

This year, both agencies made far fewer competitive awards:

Advertisement

Competitive grants at the …

Advertisement

National Institutes of Health

National Science Foundation

The White House has said it is streamlining scientific funding by eliminating wasteful spending and cutting “woke programs” that “poison the minds of Americans.”

Advertisement

But the more than 3,500 fewer competitive grants from the N.I.H. this year touched every area of biology and medicine:

Advertisement

Competitive grants awarded by the National Institutes of Health

Figures are rounded. In 2025 dollars.

Advertisement

In practice, this means thousands of very competitive projects in areas like cancer, diabetes, aging, neurological disorders and public health improvements probably went unfunded in 2025.

Similarly, at the National Science Foundation, the roughly 3,000 fewer new grants encompassed reductions to every area of science (and the social sciences):

Advertisement

New grants awarded by the National Science Foundation

Advertisement

Advertisement

Directorate 2015-24 avg. 2025 Change
Social, behavioral and economic sciences 935 501 -46%
Biology 1,143 735 -36%
Geosciences 1,483 964 -35%
STEM education 1,087 758 -30%
Computer science 2,017 1,459 -28%
Engineering 1,755 1,461 -17%
Math and physics 2,512 2,094 -17%
Technology and innovation 757 657 -13%
Office of the director 132 205 +55%
Total 11,821 8,834 -25%

Advertisement

Figures are rounded. In 2025 dollars. Table includes only directorates with spending in 2025.

There were fewer new grants awarded in biology, geosciences, STEM education, computer science and engineering, math, physics, technology and innovation.

Only the office of the director awarded more new grants this year; it funds projects that don’t neatly fall into other categories. That growth was fueled by a previously established N.S.F. goal to expand fellowships at universities in regions that have historically received less federal funding.

Advertisement

The Trump administration has also taken the unusual step of canceling thousands of active health and science grants, citing a lack of overlap with its priorities.

The website Grant Witness has estimated that the administration canceled or froze 5,415 N.I.H. grants this year, of which roughly half have been reinstated through court cases or negotiations where universities have agreed to some of the administration’s demands. And it canceled or froze 1,996 N.S.F. grants, of which nearly a third have been reinstated, according to Grant Witness estimates.

Advertisement

2. More competition

It’s simple math: Fewer grants implies more competition for federal funding.

Take the category of research grants known as R01, the oldest and most prestigious grant that the N.I.H. awards. An acceptance or rejection can make or break a scientist’s career.

Advertisement

These grants fund topics such as studying the impact of e-cigarettes on brain health, modeling the movements of mice, or devising new methods to kill mosquitoes.

Last year, only one in six were funded. But this year, the agency awarded 24 percent fewer R01 grants.

Advertisement

R01 grants awarded by the National Institutes of Health

Advertisement

This means fewer scientists had their research funded. Last year, the N.I.H.’s National Cancer Institute funded R01 applications from new investigators that fell in the top 10 percent based on scoring by the agency. But by the end of fiscal year 2025, it funded only the top 4 percent.

“Nobody believes that a fourth-percentile and a fifth-percentile grant are clearly of different quality,” Dr. Kobrin said. “It’s just not that precise a measurement.”

3. A drop in grants mentioning diversity

Advertisement

The Trump administration has prioritized eliminating research that involves diversity, equity and inclusion, and has eliminated hundreds of keywords related to diversity on federal websites.

A Times analysis found a steep reduction in the share of competitive N.I.H. grants whose titles or abstracts included flagged D.E.I.-related keywords (such as “equity,” “racial minority” or “underserved patient”) on a list shared by N.I.H. employees.

Advertisement

Share of competitive N.I.H. grants that included flagged D.E.I.-related keywords

Advertisement

The data shows a big surge in these keywords after 2020, during the Biden administration.

While some of the decline in 2025 could be attributed to a change in the language that researchers use to describe their work, it also probably reflects a drop in research related to minority health. For example, the National Institute on Minority Health and Health Disparities awarded 61 percent fewer competitive grants this year, the steepest decline at any arm of the N.I.H.

N.I.H. employees said they did not receive clear guidance on how to determine if a project was D.E.I.-related. Instead, they were sent spreadsheets of grants that had been flagged for not complying with the Trump administration’s priorities.

Advertisement

“We’re constantly hearing that things have been flagged,” Dr. Kobrin said.

“Nobody wants to acknowledge what they were flagged for.”

Advertisement

4. Fewer fellowships for future scientists

The government provides critical funds for training new scientists through graduate student, postdoctoral and early-career fellowships and grants.

The N.S.F. has run a prestigious graduate research fellowship program since 1952. It funds three years of research for around 2,000 of the country’s top science graduate students.

Advertisement

Number of graduate research fellowships awarded by the National Science Foundation

Advertisement

This year, it awarded 536 fewer such fellowships. The government originally planned to eliminate 1,000 fellowships, but later added about 500 more after facing protests from scientists and academics.

The cut affected most fields, with fellowships in four areas — life sciences, psychology, STEM education and social sciences — being cut by more than half. Fellowships in computer science, an administration priority, grew by almost 50 percent.

Advertisement

National Science Foundation graduate research fellowships

Advertisement

Advertisement
Field 2015-24 avg. 2025 Change
Life sciences 516 214 -59%
Psychology 117 56 -52%
STEM education 29 14 -52%
Social sciences 159 79 -50%
Math 90 56 -38%
Geosciences 122 84 -31%
Engineering 575 406 -29%
Chemistry 176 154 -13%
Materials research 58 63 +9%
Physics 139 166 +19%
Computer science 141 208 +48%
Total 2,121 1,500 -29%

There were also months of delays in publishing the fellowship application for next year, and new eligibility restrictions that exclude second-year Ph.D. students from applying, which may lower the numbers of fellowships in future years.

“This is an incredibly shortsighted and regressive change,” said Kevin Johnson, a former program director at N.S.F.’s geosciences directorate, because second-year graduate students are usually better prepared to conduct research.

Advertisement

“It sends a signal to future potential applicants that science is not supported and is not valued,” he said.

Early-career scientists are usually more reliant on federal funding because they have few alternatives to fund their research and training. Many go on to work in industry afterward, further fueling the economy.

In a 1945 report that led to the creation of the N.S.F., Vannevar Bush, who directed military research and development during World War II, argued that the government should invest in training the next generation of scientists to ensure American scientific progress.

Advertisement

But many experts worry that the recent funding cuts and budget reductions may threaten America’s role as a global scientific leader.

“I personally know many scientists in my field leaving the United States altogether,” Mr. Johnson said.

Advertisement
Advertisement

About the Data

For grants from the National Institutes of Health, we downloaded data from N.I.H. RePORTER from fiscal year 2015 onward, and filtered out intramural projects, R&D contracts, interagency agreements, subprojects and grants administered by other entities. We looked only at grants labeled as new (type 1) or competitive renewals (type 2, 4C and 9) that were awarded during the fiscal year. (We did not include noncompetitive renewal grants, which are ongoing annual payments to research awarded in past years.)

For grants from the National Science Foundation, we downloaded data from the N.S.F.’s award search website from fiscal year 2015 onward. We analyzed both standard grants, where all of the money is committed up front, and continuing grants, where the money is paid in annual increments. (We did not include annual payments made to grants that were awarded in prior years.) For grants that were awarded in past years, we used USASpending.gov to identify when each grant was awarded. Data for the graduate research fellowship program was retrieved from the program’s award listing.

Advertisement

All dollar figures are adjusted to August 2025 dollars, and the data is updated as of Nov. 25, 2025.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Science

Contributor: With high deductibles, even the insured are functionally uninsured

Published

on

Contributor: With high deductibles, even the insured are functionally uninsured

I recently saw a patient complaining of shortness of breath and a persistent cough. Worried he was developing pneumonia, I ordered a chest X-ray — a standard diagnostic tool. He refused. He hadn’t met his $3,000 deductible yet, and so his insurance would have required him to pay much or all of the cost for that scan. He assured me he would call if he got worse.

For him, the X-ray wasn’t a medical necessity, but it would have been a financial shock he couldn’t absorb. He chose to gamble on a cough, and five days later, he lost — ending up in the ICU with bilateral pneumonia. He survived, but the cost of his “savings” was a nearly fatal hospital stay and a bill that will quite likely bankrupt him. He is lucky he won’t be one of the 55,000 Americans to die from pneumonia each year.

As a physician associate in primary care, I serve as a frontline witness to this failure of the American approach to insurance. Medical professionals are taught that the barrier to health is biology: bacteria, viruses, genetics. But increasingly, the barrier is a policy framework that pressures insured Americans to gamble with their lives. High-deductible health plans seem affordable because their monthly premiums are lower than other plans’, but they create perverse incentives by discouraging patients from seeking and accepting diagnostics and treatments — sometimes turning minor, treatable issues into expensive, life-threatening emergencies. My patient’s gamble with his lungs is a microcosm of the much larger gamble we are taking with the American public.

The economic theory underpinning these high deductibles is known as “skin in the game.” The idea is that if patients are responsible for the first few thousand dollars of their care, they will become savvy consumers, shopping around for the best value and driving down healthcare costs.

But this logic collapses in the exam room. Healthcare is not a consumer good like a television or a used car. My patient was not in a position to “shop around” for a cheaper X-ray, nor was he qualified to determine if his cough was benign or deadly. The “skin in the game” theory assumes a level of medical literacy and market transparency that simply doesn’t exist in a moment of crisis. You can compare the specs of two SUVs; you cannot “shop around” for a life-saving diagnostic while gasping for air.

Advertisement

A 2025 poll from the Kaiser Family Foundation points to this reality, finding that up to 38% of insured American adults say they skipped or postponed necessary healthcare or medications in the past 12 months because of cost. In the same poll, 42% of those who skipped care admitted their health problem worsened as a result.

This self-inflicted public health crisis is set to deteriorate further. The Congressional Budget Office estimates roughly 15 million people will lose health coverage and become uninsured by 2034 because of Medicaid and Affordable Care Act marketplace cuts. That is without mentioning the millions more who will see their monthly premiums more than double if premium tax credits are allowed to expire. If that happens, not only will millions become uninsured but also millions more will downgrade to “bronze” plans with huge deductibles just to keep their premiums affordable. We are about to flood the system with “insured but functionally uninsured” patients.

I see the human cost of this “functional uninsurance” every week. These are patients who technically have coverage but are terrified to use it because their deductibles are so large they may exceed the individuals’ available cash or credit — or even their net worth. This creates a dangerous paradox: Americans are paying hundreds of dollars a month for a card in their wallet they cannot afford to use. They skip the annual physical, ignore the suspicious mole and ration their insulin — all while technically insured. By the time they arrive at my clinic, their disease has often progressed to a catastrophic event, from what could have been a cheap fix.

Federal spending on healthcare should not be considered charity; it is an investment in our collective future. We cannot expect our children to reach their full potential or our workforce to remain productive if basic healthcare needs are treated as a luxury. Inaction by Congress and the current administration to solve this crisis is legislative malpractice.

In medicine, we are trained to treat the underlying disease, not just the symptoms. The skipped visits and ignored prescriptions are merely symptoms; the disease is a policy framework that views healthcare as a commodity rather than a fundamental necessity. If we allow these cuts to proceed, we are ensuring that the American workforce becomes sicker, our hospitals more overwhelmed and our economy less resilient. We are walking willingly into a public health crisis that is entirely preventable.

Advertisement

Joseph Pollino is a primary care physician associate in Nevada.

Insights

L.A. Times Insights delivers AI-generated analysis on Voices content to offer all points of view. Insights does not appear on any news articles.

Viewpoint
This article generally aligns with a Center Left point of view. Learn more about this AI-generated analysis
Perspectives

The following AI-generated content is powered by Perplexity. The Los Angeles Times editorial staff does not create or edit the content.

Ideas expressed in the piece

  • High-deductible health plans create a barrier to necessary medical care, with patients avoiding diagnostics and treatments due to out-of-pocket cost concerns[1]. Research shows that 38% of insured American adults skipped or postponed necessary healthcare or medications in the past 12 months because of cost, with 42% reporting their health worsened as a result[1].

  • The economic theory of “skin in the game”—which assumes patients will shop around for better healthcare values if they have financial responsibility—fails in medical practice because patients lack the medical literacy to make informed decisions in moments of crisis and cannot realistically compare pricing for emergency or diagnostic services[1].

  • Rising deductibles are pushing enrollees toward bronze plans with deductibles averaging $7,476 in 2026, up from the average silver plan deductible of $5,304[1][4]. In California’s Covered California program, bronze plan enrollment has surged to more than one-third of new enrollees in 2026, compared to typically one in five[1].

  • Expiring federal premium tax credits will more than double out-of-pocket premiums for ACA marketplace enrollees in 2026, creating an expected 75% increase in average out-of-pocket premium payments[5]. This will force millions to either drop coverage or downgrade to bronze plans with massive deductibles, creating a population of “insured but functionally uninsured” people[1].

  • High-deductible plans pose particular dangers for patients with chronic conditions, with studies showing adults with diabetes involuntarily switched to high-deductible plans face 11% higher risk of hospitalization for heart attacks, 15% higher risk for strokes, and more than double the likelihood of blindness or end-stage kidney disease[4].

Different views on the topic

  • Expanding access to health savings accounts paired with bronze and catastrophic plans offers tax advantages that allow higher-income individuals to set aside tax-deductible contributions for qualified medical expenses, potentially offsetting higher out-of-pocket costs through strategic planning[3].

  • Employers and insurers emphasize that offering multiple plan options with varying deductibles and premiums enables employees to select plans matching their individual needs and healthcare usage patterns, allowing those who rarely use healthcare to save money through lower premiums[2]. Large employers increasingly offer three or more medical plan choices, with the expectation that employees choosing the right plan can unlock savings[2].

  • The expansion of catastrophic plans with streamlined enrollment processes and automatic display on HealthCare.gov is intended to make affordable coverage more accessible for certain income groups, particularly those above 400% of federal poverty level who lose subsidies[3].

  • Rising healthcare costs, including specialty drugs and new high-cost cell and gene therapies, are significant drivers requiring premium increases regardless of plan design[5]. Some insurers are managing affordability by discontinuing costly coverage—such as GLP-1 weight-loss medications—to reduce premium rate increases for broader plan members[5].

Advertisement
Continue Reading

Science

Trump administration slashes number of diseases U.S. children will be regularly vaccinated against

Published

on

Trump administration slashes number of diseases U.S. children will be regularly vaccinated against

The U.S. Department of Health and Human Services announced sweeping changes to the pediatric vaccine schedule on Monday, sharply cutting the number of diseases U.S. children will be regularly immunized against.

Under the new guidelines, the U.S. still recommends that all children be vaccinated against measles, mumps, rubella, polio, pertussis, tetanus, diphtheria, Haemophilus influenzae type B (Hib), pneumococcal disease, human papillomavirus (HPV) and varicella, better known as chickenpox.

Vaccines for all other diseases will now fall into one of two categories: recommended only for specific high-risk groups, or available through “shared clinical decision-making” — the administration’s preferred term for “optional.”

These include immunizations for hepatitis A and B, rotavirus, respiratory syncytial virus (RSV), bacterial meningitis, influenza and COVID-19. All these shots were previously recommended for all children.

Insurance companies will still be required to fully cover all childhood vaccines on the CDC schedule, including those now designated as optional, according to the Department of Health and Human Services.

Advertisement

Health Secretary Robert F. Kennedy Jr., a longtime vaccine critic, said in a statement that the new schedule “protects children, respects families, and rebuilds trust in public health.”

But pediatricians and public health officials widely condemned the shift, saying that it would lead to more uncertainty for patients and a resurgence of diseases that had been under control.

“The decision to weaken the childhood immunization schedule is misguided and dangerous,” said Dr. René Bravo, a pediatrician and president of the California Medical Assn. “Today’s decision undermines decades of evidence-based public health policy and sends a deeply confusing message to families at a time when vaccine confidence is already under strain.”

The American Academy of Pediatrics condemned the changes as “dangerous and unnecessary,” and said that it will continue to publish its own schedule of recommended immunizations. In September, California, Oregon, Washington and Hawaii announced that those four states would follow an independent immunization schedule based on recommendations from the AAP and other medical groups.

The federal changes have been anticipated since December, when President Trump signed a presidential memorandum directing the health department to update the pediatric vaccine schedule “to align with such scientific evidence and best practices from peer, developed countries.”

Advertisement

The new U.S. vaccination guidelines are much closer to those of Denmark, which routinely vaccinates its children against only 10 diseases.

As doctors and public health experts have pointed out, Denmark also has a robust system of government-funded universal healthcare, a smaller and more homogenous population, and a different disease burden.

“The vaccines that are recommended in any particular country reflect the diseases that are prevalent in that country,” said Dr. Kelly Gebo, dean of the Milken Institute School of Public Health at George Washington University. “Just because one country has a vaccine schedule that is perfectly reasonable for that country, it may not be at all reasonable” elsewhere.

Almost every pregnant woman in Denmark is screened for hepatitis B, for example. In the U.S., less than 85% of pregnant women are screened for the disease.

Instead, the U.S. has relied on universal vaccination to protect children whose mothers don’t receive adequate care during pregnancy. Hepatitis B has been nearly eliminated in the U.S. since the vaccine was introduced in 1991. Last month, a panel of Kennedy appointees voted to drop the CDC’s decades-old recommendation that all newborns be vaccinated against the disease at birth.

Advertisement

“Viruses and bacteria that were under control are being set free on our most vulnerable,” said Dr. James Alwine, a virologist and member of the nonprofit advocacy group Defend Public Health. “It may take one or two years for the tragic consequences to become clear, but this is like asking farmers in North Dakota to grow pineapples. It won’t work and can’t end well.”

Continue Reading

Science

For Oprah Winfrey, a croissant is now just a croissant — not a struggle

Published

on

For Oprah Winfrey, a croissant is now just a croissant — not a struggle

Yes, Oprah Winfrey has discussed her weight loss and weight gain and weight in general before — many, many times before. The difference this time around, she says, is how little food noise there is in her daily life, and how little shame. It’s so quiet, in fact, that she can eat a whole croissant and simply acknowledge she had breakfast.

“Food noise,” for those who don’t experience it, is a virtually nonstop mental conversation about food that, according to Tufts Medicine, rarely shuts up and instead drives a person “to eat when they’re not hungry, obsess over meals and feel shame or guilt about their eating habits.”

“This type of obsessive food-related thinking can override hunger cues and lead to patterns of overeating, undereating or emotional eating — especially for people who are overweight,” Tufts said.

Winfrey told People in an exclusive interview published Tuesday that in the past she would have been thinking, “‘How many calories in that croissant? How long is it going to take me to work it off? If I have the croissant, I won’t be able to have dinner.’ I’d still be thinking about that damn croissant!”

What has changed is her acceptance 2½ years ago that she has a disease, obesity, and that this time around there was something not called “willpower” to help her manage it.

Advertisement

The talk show host has been using Mounjaro, one of the GLP-1 drugs, since 2023. The weight-loss version of Mounjaro is Zepbound, like Wegovy is the weight-loss version of Ozempic. Trulicity and Victroza are also GLP-1s, and a pill version of Wegovy was just approved by the FDA.

When she started using the injectable, Winfrey told People she welcomed the arrival of a tool to help her get away from the yo-yo path she’d been on for decades. After understanding the science behind it, she said, she was “absolutely done with the shaming from other people and particularly myself” after so many years of weathering public criticism about her weight.

“I have been blamed and shamed,” she said elsewhere in that 2023 interview, “and I blamed and shamed myself.”

Now, on the eve of 2026, Winfrey says her mental shift is complete. “I came to understand that overeating doesn’t cause obesity. Obesity causes overeating,” she told the outlet. “And that’s the most mind-blowing, freeing thing I’ve experienced as an adult.”

She isn’t even sharing her current weight with the public.

Advertisement

Winfrey did take a break from the medication early in 2024, she said, and started to regain weight despite continuing to work out and eat healthy foods. So for Winfrey the obesity prescription will be renewed for a lifetime. C’est la vie seems to be her attitude.

“I’m not constantly punishing myself,” she said. “I hardly recognize the woman I’ve become. But she’s a happy woman.”

Winfrey has to take a carefully managed magnesium supplement and make sure she drinks enough water, she said. The shots are done weekly, except when she feels like she can go 10 or 12 days. But packing clothes for the Australian leg of her “Enough” book tour was an off-the-rack delight, not a trip down a shame spiral. She’s even totally into regular exercise.

Plus along with the “quiet strength” she has found in the absence of food noise, Winfrey has experienced another cool side effect: She pretty much couldn’t care less about drinking alcohol.

“I was a big fan of tequila. I literally had 17 shots one night,” she told People. “I haven’t had a drink in years. The fact that I no longer even have a desire for it is pretty amazing.”

Advertisement

So back to that croissant. How did she feel after she scarfed it down?

“I felt nothing,” she said. “The only thing I thought was, ‘I need to clean up these crumbs.’”

Continue Reading

Trending